AstraZeneca India comprises two main entities and plays a significant role in the global operations of AstraZeneca:
Established in 1979 and headquartered in Bengaluru, AZPIL is a science-led biopharmaceutical company focused on developing and commercializing prescription medicines across therapeutic areas like Oncology, Cardiovascular, Renal & Metabolism, Respiratory, and Rare Diseases. It also hosts a world-class manufacturing facility in Bengaluru and employs over 600 people.
In FY 2024–25, AZPIL achieved a remarkable 32% year-on-year revenue growth, crossing ₹1,700 crore (~$200 million). Notable approvals included Palivizumab for RSV prevention and Tremelimumab combined with Durvalumab for certain liver cancers.
In 2024, AZPIL partnered with Mankind Pharma for the exclusive distribution of Symbicort (budesonide + formoterol) in India—while retaining IP and regulatory control—to enhance asthma treatment accessibility.
Recently, the company also received regulatory approval to import and sell Lokelma (sodium zirconium cyclosilicate powder) for treating hyperkalaemia in adults.
In July 2024, AZIPL announced a ₹250 crore investment to expand its Global Innovation & Technology Centre (GITC) in Chennai, aiming to create 1,300 high-skilled roles by 2025.
In June 2025, the company further expanded its Bengaluru Global Hub with a ₹166 crore infusion, adding 400 jobs and bringing the hub's capacity to approximately 1,300 staff. The facility emphasizes AI-powered innovation, data analytics, R&D support, and global regulatory operations.
AZIPL supports approximately 4,000 employees, contributing to major innovation and business services globally, while also earning recognition as a Great Place to Work (7th consecutive year) and ranking among the Top 50 workplaces for women in India.
Innovation and Scale: AstraZeneca India is evolving—from traditional pharmaceutical operations (AZPIL) to a modern technology and innovation powerhouse (AZIPL).
Growing Footprint: Sustained investments in Chennai and Bengaluru underscore the company’s ambitions to leverage India’s talent for global R&D and business services excellence.
Strong Growth & Leadership: AZPIL’s robust financial performance and AZIPL’s awards in workplace culture reflect well-rounded success.
Patient-Centric Collaborations: Partnerships like Symbicort distribution and new drug introductions illustrate AstraZeneca’s focus on improving access to vital therapies in India.
Situated in one of Bengaluru’s largest tech parks—Embassy Manyata Business Park (also known as Manyata Tech Park)—this campus spans nearly 10 million square feet across approximately 300 acres. The park houses diverse tenants across IT, pharma, manufacturing, and financial services.